Pregnant women represent a unique population for correctional facilities to care for. The incarcerated pregnant population is at an increased risk of concurrent opioid use disorder (OUD) that requires specialized care. The evidence-based best practice and standard of care for pregnant women with OUD is medication-assisted treatment (MAT) with methadone or buprenorphine pharmacotherapy. Correctional facilities that house women must be prepared to provide this care in a timely manner upon intake in order to address the serious medical needs of the pregnant woman and her fetus. Providing MAT in the incarceration setting has distinctive logistics that must be considered. This article recommends strategies to optimize the care of pregnant incarcerated women with OUD, emphasizing the importance of appropriate counseling and treatment with opioid agonist pharmacotherapy.
American College of Obstetricians and Gynecologists Committee on Obstetric Practice &American Society of Addiction Medicine. (2017). Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstetrics and Gynecology, 130, e81–e94.
BinswangerI. A., BlatchfordP. J., MuellerS. R., SternM. F. (2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159, 592–600.
5.
BronsonJ., StroopJ., ZimmerS., BerzofskyM. (2017). Drug use, dependence, and abuse among state prisoners and jail inmates, 2007-2009 (NCJ 250546). Washington, DC: Bureau of Justice Statistics.
6.
CarsonE. A., AndersonE. (2015). Prisoners in 2015 (NCJ 250229). Washington, DC: Bureau of Justice Statistics.
7.
CarsonE. A. (2018). Prisoners in 2016 (NCJ 251149). Washington, DC: Bureau of Justice Statistics.
8.
Center for Behavioral Health Statistics and Quality. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). Rockville, MD. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.htm
ChandlerR. K., FletcherB. W., VolkowN. D. (2009). Treating drug abuse and addiction in the criminal justice system: Improving public health and safety. Journal of the American Medical Association, 301, 183–190. doi:10.1001/jama.2008.976
11.
DayE., StrangJ. (2011). Outpatient versus inpatient opioid detoxification: A randomized controlled trial. Journal of Substance Abuse Treatment, 40, 56–66.
FiscellaK. (2016). Guidelines and quality measures should reflect evidence for effectiveness of naltrexone. Journal of Addiction Medicine, 10, 453.
15.
GrootE., KouyoumdjianF. G., KieferL., MadadiP., GrossJ., PrevostB.…PersaudN. (2016). Drug toxicity deaths after release from incarceration in Ontario, 2006-2013: Review of coroner’s cases. PLoS One, 11, e0157512. doi:10.1371/journal.pone.0157512
16.
HaightS. C., KoJ. Y., TongV. T., BohmM. K., CallaghanW. M. (2018). Opioid use disorder documented at delivery hospitalization—United States, 1999-2014. Morbidity and Mortality Weekly Report, 67, 1–5.
17.
JonesH. E., KaltenbachK., HeilS. H., StineS. M., CoyleM. G., ArriaA. M.…FischerG. (2010). Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine, 363, 2320–2331. doi:10.1056/NEJMoa1005359
18.
JonesH. E., O’GradyK. E., MalfiD., TutenM. (2008). Methadone maintenance vs. methadone taper during pregnancy: Maternal and neonatal outcomes. American Journal on Addictions, 17, 372–386. doi:10.1080/10550490802266276
19.
JonesH. E., TerplanM., MeyerM. (2017). Medically assisted withdrawal (detoxification): Considering the mother-infant dyad. Journal of Addition Medicine, 11, 90–92. doi:10.1097/ADM.0000000000000289
20.
KampmanK., JarvisM. (2015). American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. Journal of Addiction Medicine, 9, 358–367.
21.
KelseyC. M., MedelN., MullinsC., DallaireD., ForestellC. (2017). An examination of care practices of pregnant women incarcerated in jail facilities in the United States. Maternal and Child Health Journal, 21, 1260–1266. doi:10.1007/s10995-016-2224-5
22.
KouyoumdjianF. G., McIsaacK. E., LiauwJ., GreenS., KarachiwallaF., SiuW.…HwangS. W. (2015). A systematic review of randomized controlled trials of interventions to improve the health of persons during imprisonment and in the year after release. American Journal of Public Health, 105, e13–e33.
23.
KransE. E., CochranG., BogenD. L. (2015). Caring for opioid-dependent pregnant women: Prenatal and postpartum care considerations. Clinical Obstetrics and Gynecology, 58, 370–379. doi:10.1097/GRF.0000000000000098
24.
LeeJ. D., FriedmannP. D., KinlockT. W., NunesE. V., BoneyT. Y., HoskinsonR. A.Jr…O’BrienC. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine, 374, 1232–1242.
25.
MaruschakL. M. (2006). Medical problems of jail inmates (NCJ 210696). Washington, DC: Bureau of Justice Statistics.
26.
MaruschakL. M. (2008). Medical problems of prisoners (NCJ 221740). Washington, DC: Bureau of Justice Statistics.
27.
MattickR. P., BreenC., KimberJ., DavoliM. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, 2009, CD002209. doi:10.1002/14651858.CD002209.pub2
MitchellS. G., KellyS. M., BrownB. S., ReisingerH. S., PetersonJ. A., RuhfA.…SchwartzR. P. (2009). Incarceration and opioid withdrawal: The experiences of methadone patients and out-of-treatment heroin users. Journal of Psychoactive Drugs, 41, 145–152.
30.
MurphyK., BeckerM., LockeJ., KelleherC., McLeodJ., IsasiF. (2016). Finding solutions to the prescription opioid and heroin crisis: A road map for states. Washington, DC: National Governors Association Center for Best Practices.
NunnA., ZallerN., DickmanS., TrimburC., NijhawanA., RichJ. D. (2009). Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug and Alcohol Dependence, 105, 83–88.
34.
Office on Women’s Health. (2016). White paper: Opioid use, misuse, and overdose in women. Washington, DC: U.S. Department of Health and Human Services.
35.
RichJ. D., McKenzieM., LarneyS., WongJ. B., TranL., ClarkeJ.…ZallerN. (2015). Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: A randomised, open-label trial. Lancet, 386, 350–359.
36.
RichJ. D., WakemanS. E., DickmanS. L. (2011). Medicine and the epidemic of incarceration in the United States. New England Journal of Medicine, 364, 2081–2083.
37.
RuddR. A., SethP., DavidF., SchollL. (2016). Increases in drug and opioid-involved overdose deaths—United States, 2010-2015. Morbidity and Mortality Weekly Report, 65, 1445–1452. doi:10.15585/mmwr.mm655051e1
38.
SchuckitM. A. (2016). Treatment of opioid-use disorders. New England Journal of Medicine, 375, 357–368.
StatonM., LeukefeldC., WebsterJ. M. (2003). Substance use, health, and mental health: Problems and service utilization among incarcerated women. International Journal of Offender Therapy and Comparative Criminology, 47, 224–239.
41.
Substance Abuse and Mental Health Services Administration. (2005). Results from the 2004 National Survey on Drug Use and Health: National findings (HHS Publication No. SMA 05-4062). Rockville, MD.
Substance Abuse and Mental Health Services Administration. (2012). Medication-assisted treatment for opioid addiction in opioid treatment programs (Treatment Improvement Protocol [TIP] Series 43, HHS Publication No. SMA 12-4214). Rockville, MD.
44.
Substance Abuse and Mental Health Services Administration. (2014). Methadone treatment for pregnant women (HHS Publication No. SMA 14-4124). Rockville, MD.
SufrinC., Kolbi-MolinasA., RothR. (2015). Reproductive justice, health disparities and incarcerated women in the United States. Perspectives on Sexual and Reproductive Health, 47, 213–219.
48.
TerplanM., LairdH. J., HandD. J., WrightT. E., PremkumarA., MartinC. E.…KransE. E. (2018) Opioid detoxification during pregnancy: A systematic review. Obstetrics and Gynecology, 131, 803–814.
49.
ToliaV. N., PatrickS. W., BennettM. M., MurthyK., SousaJ., SmithP. B.…SpitzerA. R. (2015). Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. New England Journal of Medicine, 372, 2118–2126.
50.
VolkowN. D., KoobG. F., McLellanA. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374, 363–371.
51.
WaalH. (2013). Is sustained release naltrexone an option for heroin-dependent pregnant women?. Addiction, 108, 252–253.
WangM. J., KuperS. G., SimsB., PaddockC. S., DantlzerJ., MuirS., HarperL. M. (2018). Opioid detoxification in pregnancy: Systematic review and meta-analysis of perinatal outcomes. American Journal of Perinatology, epub ahead of print.
ZedlerB. K., MannA. L., KimM. M., AmickH. R., JoyceA. R., MurrelleE. L., JonesH. E. (2016). Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: A systematic review and meta-analysis of safety in the mother, fetus and child. Addiction, 111, 2115–2128.
57.
ZengZ. (2018). Jail inmates in 2016. NCJ 251210. Washington, DC: Bureau of Justice Statistics.
